Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasalfent for Breakthrough Cancer Pain
NCT00459277Phase 3Completed
- Start
- Dec 2006
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breakthrough cancer pain (BTcP) comparing Nasalfent with Placebo (2 arms). Primary endpoint: Summed Pain Intensity Difference at 30 Minutes. Started Dec 2006; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00459277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00459277.